Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06470711 · ClinicalTrials.gov registry record
Mapping of Electrical Properties in the Brain
A clinical trial of Malignant Glioma, sponsored by Mayo Clinic.
- Recruiting
- Registry status
- 120
- Enrollment target
- 1
- Study location
NCT06470711: Recruiting study of Malignant Glioma, sponsored by Mayo Clinic.
NCT06470711 is a study of Malignant Glioma that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 120 participants, above the 89-participant average among 40 other Malignant Glioma trials with a reported enrollment target (35% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06470711, a study of Malignant Glioma, is actively recruiting participants, sponsored by Mayo Clinic.
- RECRUITING
- Registry status
- 120 participants
- Enrollment target
- 1
- Study location
Study Summary
This study evaluates imaging methods for monitoring neural and electrical activity in the brain for improving clinical diagnosis.
Primary Outcome
At least 4 normal white matter regions of the brain will be analyzed. Fractional anisotropy (FA) and optimized diagnostic imaging (ODI) values will be compared to determine alignment within normal healthy white matter tracts (e.g. cortical spinal tract, corpus callosum).
Conditions Studied
Interventions
- OTHER Non-Interventional Study
Study Locations (1)
Arizona
- Mayo Clinic in Arizona - Scottsdale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2024-09-13 |
| Est. Completion | 2027-09-30 |
What NCT06470711 shows while recruiting
NCT06470711 is an observational study that tracks outcomes without assigning an intervention. The registered 120 participants enrollment target is mid-sized for trials with a published cap, above the 89-participant average among 40 other Malignant Glioma trials with a reported enrollment target (35% higher).
The record links to 1 condition, with Malignant Glioma appearing as the primary indexed condition, and to 1 intervention - of which Non-Interventional Study is the first listed.
NCT06470711 reports a single indexed study location in Arizona.
Frequently Asked Questions
What is clinical trial NCT06470711 about?
NCT06470711 is a clinical study titled "Mapping of Electrical Properties in the Brain". This study evaluates imaging methods for monitoring neural and electrical activity in the brain for improving clinical diagnosis.
What is the current status of trial NCT06470711?
This trial is currently recruiting. The enrollment target is 120 participants. The study started on 2024-09-13. Estimated completion is 2027-09-30.
What conditions does trial NCT06470711 study?
This clinical trial studies the following conditions: Malignant Glioma.
What interventions are being tested in trial NCT06470711?
The interventions under investigation include: Non-Interventional Study (OTHER).
Who is sponsoring clinical trial NCT06470711?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06470711 being conducted?
This trial has 1 study location across Arizona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Malignant Glioma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06470711's enrollment target sits among peer trials
120 5th of 40 higher than 36 of 40 other Malignant Glioma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Malignant Glioma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
CARv3-TEAM-E T Cells in Glioblastoma
RECRUITING · Phase 1
-
Serial Advanced Magnetic Resonance Imaging Scan for Guidance of Personalized Adaptive Radiotherapy for High Grade Glioma
RECRUITING
-
Fitness and Nutrition in Glioma
RECRUITING · NA
-
Panitumumab-IRDye800 in Diagnosing Participants With Malignant Glioma Undergoing Surgery
RECRUITING · Phase 1
-
A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)
RECRUITING · Phase 1
-
Intratumoral Extracellular Metabolic Impact of DFMO and AMXT 1501 in Patients With Diffuse or High Grade Glioma
RECRUITING · Early Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01174108 · 120 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells
- NCT01627301 · 120 participants · NA
Sympathetic Overactivity in Post-traumatic Stress Disorder
- NCT02025023 · 120 participants · Phase 3
Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study
- NCT02128906 · 120 participants · Phase 2
Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI